
Tesaro was founded in 2010 by Mary Lynne Hedley, Frank Diehl, and Barbara Kosoff, initially as a spinout from Biogen, where Hedley and Diehl worked.
The company's first product, varlizumab, was acquired from Biogen in 2010 and was being developed for the treatment of B-cell acute lymphoblastic leukemia.
Tesaro's early focus was on oncology, with a goal of developing innovative treatments for patients with cancer.
The company's name, Tesaro, is derived from the Greek word "tesaurus", meaning treasure, reflecting the founders' aim to uncover and develop valuable treatments for patients.
About Tesaro
Tesaro is a biopharmaceutical company that was founded in 2010 by Mary Lynne Hedley and Manuel Llorente.
The company is headquartered in Waltham, Massachusetts, and has a presence in Europe through its subsidiary, Tesaro Europe Limited.
Tesaro is focused on developing and commercializing innovative therapies for cancer and other serious diseases.
Company Overview
Tesaro is a biopharmaceutical company that focuses on developing and commercializing therapies for cancer treatment.
The company was founded in 2010 by Mary Lynne Hedley and Manuel Llano.
Tesaro is headquartered in Waltham, Massachusetts, and has a global presence with operations in Europe and the US.
Tesaro's product portfolio includes Zejula, a PARP inhibitor for the maintenance treatment of ovarian cancer.
Zejula was approved by the FDA in March 2017 for the maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Tesaro was acquired by GlaxoSmithKline in May 2019 for approximately $5.1 billion.
Readers also liked: Deferred Compensation Tax Treatment for Employer
History
Tesaro was founded in 2010 by Mary Lynn Pantages, who served as the company's CEO until 2015.
The company's early years were marked by a focus on developing innovative treatments for cancer and other serious diseases.
Tesaro's first product, rolapitant, was approved by the FDA in 2014 for the prevention of delayed chemotherapy-induced nausea and vomiting.
This marked a significant milestone for the company, demonstrating its ability to develop and bring to market effective treatments for patients in need.

Tesaro's commitment to advancing cancer care led to the development of niraparib, a targeted therapy for ovarian cancer that was approved by the FDA in 2017.
Niraparib has since become a key treatment option for patients with advanced ovarian cancer, offering a new hope for those facing this challenging disease.
GSK acquired Tesaro in 2019, expanding its presence in the oncology market and providing new opportunities for the company's innovative treatments.
Acquisition and News
GlaxoSmithKline (GSK) acquired US-based biopharmaceutical company Tesaro for an aggregate cash consideration of $5.1 billion.
The acquisition was completed in December 2018 and was announced on December 3, 2018. It was carried out through GSK's indirect wholly-owned subsidiary Adriatic Acquisition Corporation.
GSK plans to use Tesaro's assets to strengthen its pharmaceutical business and accelerate the build of its oncology pipeline and commercial footprint.
Tesaro's marketed product, Zejula (niraparib), is an oral poly ADP ribose polymerase (PARP) inhibitor approved for treating ovarian cancer. It was approved in the US and Europe as a treatment for adult patients with recurrent ovarian cancer.
A unique perspective: Gsk Plc News
Zejula's revenues in its current approved indication as a second-line maintenance treatment for ovarian cancer were $166 million for the nine months ended September 30, 2018.
GSK believes PARP inhibitors also offer opportunities for use in treating multiple cancer types, including lung, breast, and prostate cancer.
The acquisition of Tesaro is expected to complete in the first quarter of 2019, subject to satisfaction of customary closing conditions.
Here are the key dates related to the acquisition:
GSK said it is in discussions with several key executives of Tesaro to ensure their continued employment with the company.
Management and Governance
Tesaro's management team is led by Lonnie Moulder, who has been the company's CEO since March 25, 2010. He is 67 years old.
Mary Lynne Hedley serves as the President of the company, a role she took on in May 2010. She is 62 years old.
The company's Board of Directors includes Mary Lynne Hedley, who has been a Director since March 25, 2010. Lonnie Moulder and Arnold Lewis Oronsky are also Directors, with Moulder joining the Board in March 2012 and Oronsky in May 2011.
For another approach, see: 5 Years
Managers and Directors
The management team at TESARO Inc is led by Lonnie Moulder, who has been serving as CEO since March 25, 2010.
Lonnie Moulder is 67 years old and has been with the company since 2010.
Mary Lynne Hedley is the President of the company, a role she has held since May 26, 2010.
She is also a Director/Board Member, a position she took on March 25, 2010.
Lonnie Moulder is also a Director/Board Member, a role he started on March 25, 2012.
Arnold Lewis Oronsky is another Director/Board Member, a position he has held since May 31, 2011.
Here is a list of the company's top managers and directors:
Patents
Tesaro has a significant patent portfolio, with a total of 40 patents filed. This demonstrates the company's commitment to innovation and intellectual property.
One of these patents, filed on May 9, 2018, has been granted and is titled "Combination therapies for treating cancer". This patent has a grant date of December 3, 2024.
The related topics for this patent include experimental cancer drugs, monoclonal antibodies, antineoplastic drugs, monoclonal antibodies for tumors, and cancer treatments.
Readers also liked: Yorkshire Patent Steam Wagon Co.
Related Topics
Tesaro is a company that has made significant contributions to the field of oncology, particularly in the development of PARP inhibitors.
Cancer is a leading cause of death worldwide, and research into new treatments is crucial.
Glaxosmithkline is a major player in the pharma & biotech industry, and its partnerships with companies like Tesaro have led to breakthroughs in cancer treatment.
Tesaro's work on PARP inhibitors has shown promise in treating certain types of cancer, including ovarian cancer.
Oncology is a field that requires innovative thinking and collaboration between companies and researchers.
PARP inhibitors, like those developed by Tesaro, work by blocking the action of a protein called PARP, which is involved in DNA repair.
Here are some key players in the pharma & biotech industry that are working on cancer treatments:
- Glaxosmithkline
- Tesaro
Frequently Asked Questions
Is TESARO a drug for ovarian cancer?
Yes, TESARO is a medication used to treat ovarian cancer, specifically for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It's indicated for maintenance treatment after a response to platinum-based chemotherapy.
What is the stock price of TESARO today?
The current stock price of TESARO Inc is $74.96. Check the latest market data for the most up-to-date information.
Featured Images: pexels.com


